Journal: Oncotarget

Article Title: Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin

doi:

Figure Lengend Snippet: A. Cytotoxic effect of KPT-251 (up), KPT-276 (middle) and selinexor (down) in combination with YM155. DMPM cells were exposed to SINE and YM155 for 72 hours, and the cytotoxic effect was assessed by MTS assay. Black lines represent the expected additive effect of the combination, calculated as the product of the effects of the individual drugs, according to the method of Kern et al . Data are expressed as percentage values of growth in treated cells compared to cells exposed to 0.01% DMSO (ctr), and represent mean values ±SD of at least three independent experiments. CI was calculated according to Chou and Talalay . B. Assessment of caspase-3 catalytic activity at 72 hours after treatment with selinexor and YM155, alone and in combination. Data are expressed as relative fluorescence units and represent the mean values ±SD of at least three independent experiments. ** P < 0.001, * P < 0.01, vs single treatments.

Article Snippet: For in vitro studies, KPT-251, KPT-276, selinexor (provided by Karyopharm Therapeutics Inc.), and YM155 (purchased from Selleck Chemicals; #S1130) were initially dissolved in DMSO, stored at −20°C, and diluted in complete culture medium immediately before use.

Techniques: MTS Assay, Activity Assay, Fluorescence

Journal: Oncotarget

Article Title: Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin

doi:

Figure Lengend Snippet: A. Tumor growth curves of STO cells subcutaneously injected into right flank of nude mice. Mice (eight mice/group) were randomly grouped to receive vehicle, KPT-251 (50 mg/kg, q3-4d × 8), KPT-276 (50 mg/kg, 5d/w × 3w) or selinexor (10 mg/kg, q3-4d × 8). The treatment started 4 (early-stage tumor; up) or 26 days (late-stage tumor; down) after cell injection. The treatment duration is indicated by the gray bar. B. Tumor growth curves of MesoII fragments subcutaneously implanted into right flank of nude mice. Mice (eight mice/group) were randomly grouped to receive vehicle or selinexor (10 mg/kg, q3-4d × 8). The treatment started 4 (early-stage tumor; up) or 28 days (late-stage tumor; down) after tumor fragments implant. The treatment duration is indicated by the gray bar. C. Representative photograph showing the growth pattern of STO cells following xenotransplantation in the peritoneal cavity of SCID mice. Arrow indicates the tumor mass and widespread tumor nodes. D. Orthotopic tumor weight distribution. Mice (nine mice per group) were randomly grouped to receive vehicle or selinexor (10 mg/kg, q3-4d × 8). The treatment started the day after cells injection and stopped 25 days after cells injection (i.e. 24 hours after the last drug treatment). E. Photographs of tumors from five representative mice per experimental group reported in D. F. Representative hematoxylin-eosin (H/E), TUNEL and survivin staining performed in FFPE sections of tumors from the experimental groups reported in D. Images for one representative mouse per group are shown. Original magnification: x40. G. Western immunoblotting showing the survivin expression in tumors from four representative mice per experimental group reported in D.

Article Snippet: For in vitro studies, KPT-251, KPT-276, selinexor (provided by Karyopharm Therapeutics Inc.), and YM155 (purchased from Selleck Chemicals; #S1130) were initially dissolved in DMSO, stored at −20°C, and diluted in complete culture medium immediately before use.

Techniques: Injection, TUNEL Assay, Staining, Western Blot, Expressing